SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Company Overview - SciSparc Ltd. is a specialty clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and cannabinoid pharmaceuticals [5] - The company is engaged in drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, pain, and autism spectrum disorder (ASD) [5] Recent Developments - MitoCareX Bio Ltd., a venture of SciSparc, has appointed Professor Nir Peled to its scientific advisory board, enhancing its expertise in cancer therapeutics [1][4] - MitoCareX is focused on drug discovery targeting the mitochondrial SLC25 protein family, with recent validation of its target using Non-Small Cell Lung Cancer (NSCLC) cells [4] Research and Contributions - Professor Peled is a recognized expert in thoracic oncology with over 250 peer-reviewed publications, contributing significantly to lung cancer research and treatment [2][3] - His work includes personalized targeted therapy, immunotherapy, biomarker development, and early detection of lung cancer [3] Technological Advancements - MitoCareX has utilized advanced computational drug discovery platforms, including the proprietary MITOLINE™ algorithm, to screen millions of small molecules for potential anti-cancer treatments [4]